London-based Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, is committed to advancing therapies for autoimmune and inflammatory diseases. Its flagship product offering, nomacopan, a second-generation complement inhibitor, is designed to attenuate the effects of inflammation and thrombosis characteristic to ailments such as paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid.
Akari Therapeutics Plc's ticker is AKTX
The company's shares trade on the NASDAQ stock exchange
They are based in London, England
There are 1-10 employees working at Akari Therapeutics Plc
It is https://www.akaritx.com/
Akari Therapeutics Plc is in the Healthcare sector
Akari Therapeutics Plc is in the Biotechnology industry
The following five companies are Akari Therapeutics Plc's industry peers: